Thalia Therapeutics acquires US firm backed by fundraise
Posted:
AIM-listed biotechnology company Thalia Therapeutics has announced the acquisition of US-based oncology firm Sanmirna Therapeutics alongside an oversubscribed £2.75m fundraise.
Alzheimer’s disease is the most common cause of dementia, responsible for up to 80% of dementia cases worldwide.
In a mouse model, KCL-286, a drug that has passed phase 1 trials for spinal injuries in people, repaired DNA breaks and…
Neko Health has raised US$700m to fund its first US expansion, new clinics and further development of its preventative health tech.
The Series C round follows a US$260m Series B in January 2025.
Founded by Spotify’s Daniel Ek and Hjalmar…
Attendees
Sponsors and Exhibitors
Contact us